Budget impact analysis of a new prostate cancer risk index for prostate cancer detection

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 3, 2011, Pages 253-261

  Nichol, M B ^a   Wu, J ^a   An, J J ^a   Huang, J ^b   Denham, D ^b   Frencher, S ^c   Jacobsen, S J ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b BECKMAN COULTER INC   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

budget impact analysis; free PSA; precursor form p2PSA; prostate cancer risk index; prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BUDGET IMPACT ANALYSIS; CANCER DIAGNOSIS; CANCER RISK; COST BENEFIT ANALYSIS; COST MINIMIZATION ANALYSIS; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK REDUCTION; TREATMENT PLANNING;

AGED; BUDGETS; COMPUTER SIMULATION; EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 80054735054     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.16     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249
2. Stark JR, Mucci L, Rothman KJ, Adami HO. Screening for prostate cancer remains controversial. BMJ 2009; 339: b3601
3. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009; 182: 2232-2241
4. Wolf AM, Wender RC, Etzioni RB, Thompson IM, DAmico AV, Volk RJ et al. American Cancer Society guidelines for the early detection of cancer: update 2010. Ca Cancer J Clin 2010; 60: 70-98
5. Bretton PR. Prostate-specific antigen and digital rectal examination in screening for prostate cancer-a community-based study. Southern Med J 1994; 87: 720-723 (Pubitemid 24218225)
6. Muschenheim F, Omarbasha B, Kardjian PM, Mondou EN. Screening for carcinoma of the prostate with prostate specific antigen. Ann Clin Lab Sci 1991; 21: 371-380
7. Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993; 42: 365-374 (Pubitemid 23314326)
8. Brawer MK. Prostate-specific antigen: current status. Ca-Cancer J Clin 1999; 49: 264-281 (Pubitemid 30142820)
9. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294: 66-70 (Pubitemid 41002840)
10. Nadler RB, Loeb S, Roehl KA, Antenor JA, Eggener S, Catalona WJ. Use of 2.6Ng/Ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol 2005; 174: 2154-2157 (Pubitemid 41611762)
11. Makarov DV, Humphreys EB, Mangold LA, Walsh PC, Partin AW, Epstein JI et al. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. J Urol 2006; 176: 554-558 (Pubitemid 43927930)
12. Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG et al. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila Pa) 2008; 1: 167-173
13. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ 2007; 176: 1853-1858 (Pubitemid 46999868)
14. Brawley OW, Ankerst DP, Thompson IM. Screening for prostate cancer. CA Cancer J Clin 2009; 59: 264-273
15. Makarov DV, Loeb S, Getzenberg RH, Partin AW. Biomarkers for prostate cancer. Annu Rev Med 2009; 60: 139-151
16. Bangma CH, van Schaik RH, Blijenberg BG, Roobol MJ, Lilja H, Stenman UH. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer. Eur J Cancer 2010; 46: 3109-3119
17. Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 2010; 28: 2493-2498
18. Sokoll LJ, Chan DW, Mikolajczyk SD, Rittenhouse HG, Evans CL, Linton HJ et al. Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: preliminary analysis. Urology 2003; 61: 274-276 (Pubitemid 36206515)
19. Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW et al. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol 2003; 170: 723-726 (Pubitemid 36999539)
20. Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG et al. 2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 2008; 180: 539-543
21. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH et al. A multicenter study of [-2]Pro-prostatespecific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011; 185: 1650-1655
22. Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 57: 921-927
23. Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA et al. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010; 183: 1355-1359
24. Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D et al. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Prev Med 2004; 38: 732-744 (Pubitemid 38757522)
25. Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate-specific antigen test among US men: findings from the 2005 national health interview survey. Cancer Epidem Biomar 2008; 17: 636-644 (Pubitemid 351469214)
26. Lacher DA, Thompson TD, Hughes JP, Saraiya M. Total, free, and percent free prostate-specific antigen levels among U.S. men, 2001-04. Adv Data 2006; 379: 1-12
27. Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 1996; 47: 863-869 (Pubitemid 26198913)
28. Crawford ED, Abrahamsson PA. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 2008; 54: 262-273
29. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horninger W et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4ng/ml prostate specific antigen. J Urol 2004; 171 (Pt 1): 2239-2244 (Pubitemid 38625443)
30. Catalona WJ, Loeb S. Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values. J Natl Compr Canc Netw 2010; 8: 265-270
31. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ et al. Measurement of prostate-specific antigen in serum as a screening-test for prostate-cancer. N Engl J Med 1991; 324: 1156-1161
32. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-534 (Pubitemid 43898816)
33. Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005; 97: 433-438 (Pubitemid 40528606)
34. Smith DS, Bullock AD, Catalona WJ. Racial differences in operating characteristics of prostate cancer screening tests. J Urol 1997; 158: 1861-1865
35. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health 2007; 10: 336-347 (Pubitemid 47481105)
36. Wolters T, van der Kwast TH, Vissers CJ, Bangma CH, Roobol M, Schröder FH et al. False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol 2010; 34: 35-43
37. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG, Pileblad E. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol 2003; 169: 1720
38. van der Cruijsen-Koeter IW, van der Kwast TH, Schroder FH. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 95; 1462: 2003
39. Hoedemaeker RF, van der Kwast TH, Boer R, de Koning HJ, Roobol M, Vis AN et al. Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst 2001; 93: 1153
40. Postma R, Roobol M, Schroder FH, van der Kwast TH. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. Cancer 2004; 100: 968
41. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004; 100: 1397
42. Schröder FH, Bangma CH, Roobol MJ. Is it necessary to detect all prostate cancers in men with serum PSA levels o3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Eur Urol 2008; 53: 901-908
43. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL et al. Prevalence of prostate cancer among men with a prostate-specific antigen level o4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246
44. Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y et al. Prostate-specific antigen cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002; 60: 469-473 discussion 473-4 (Pubitemid 35292175)
45. Meeks JJ, Loeb S, Helfand BT, Kan D, Smith ND, Catalona WJ. Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml. J Urol 2009; 181: 2515-2518
46. Kaplan DJ, Boorjian SA, Ruth K, Egleston BL, Chen DY, Viterbo R et al. Evaluation of the prostate cancer prevention trial risk calculator in a high-risk screening population. Bju Int 2010; 105: 334-337